BenevolentAI lays off around 180 staffers, cuts pipeline programs in reorg
London-based AI drug discovery company BenevolentAI is laying off about 180 employees as part of a restructuring plan that resulted from a strategic review.
By slashing the headcount, reducing its lab footprint and halting certain drug programs, BenevolentAI hopes to free up more than $55 million (£45 million) and extend the cash runway from Q4 2024 into July 2025, even without new revenue. Amid the changes, CFO Nicholas Keher has also resigned.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters